A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

We evaluated the safety and biologic activity of the BH3 mimetic protein, navitoclax, combined with rituximab, in comparison to rituximab alone. One hundred and eighteen patients with chronic lymphocytic leukemia (CLL) were randomized to receive eight weekly doses of rituximab (arm A), eight weekly...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Leuk Lymphoma
Main Authors: Kipps, Thomas J., Eradat, Herbert, Grosicki, Sebastian, Catalano, John, Cosolo, Walter, Dyagil, Iryna S., Yalamanchili, Sreeni, Chai, Akiko, Sahasranaman, Srikumar, Punnoose, Elizabeth, Hurst, Deborah, Pylypenko, Halyna
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643417/
https://ncbi.nlm.nih.gov/pubmed/25797560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1030638
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki